Memantine Mylan

Memantine Hydrochloride, the active ingredient in Memantine Mylan, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults, helping to preserve cognitive function and daily living activities.

GNH USA supplies Memantine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality, regulatory compliance, and timely delivery across Europe, Asia, Africa and the Americas.

Memantine Mylan, a non‑competitive NMDA receptor antagonist, modulates glutamate‑mediated excitotoxicity and is employed in the therapeutic management of Alzheimer’s disease. - Moderate to severe Alzheimer’s disease: improves cognition and functional abilities in patients. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression. - Functional decline in Alzheimer’s disease: helps maintain activities of daily living.

Memantine Mylan may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements or hard stools. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - Seizures: rare occurrence of convulsive episodes. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hallucinations or psychosis: rare neuropsychiatric events.

When prescribing Memantine Mylan, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose or monitor renal function in patients with reduced kidney function. - History of seizures: use with caution as the drug may lower seizure threshold. - Cardiovascular disease: monitor blood pressure and heart rate in patients with existing cardiac conditions. - Concomitant use with other NMDA antagonists: avoid additive neuro‑psychiatric effects. - Pregnancy and lactation: risk unknown; use only if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Memantine Mylan can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Amantadine: combined use may increase risk of neuropsychiatric side effects. - Ketamine: additive NMDA antagonism can lead to excessive CNS depression. - High‑dose zinc supplements: may reduce memantine absorption.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may blunt cognitive benefits of memantine. - CNS depressants (e.g., benzodiazepines): monitor for enhanced sedation. - Proton pump inhibitors: may slightly increase memantine plasma levels.